First-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W_pro1 (BNT112) monotherapy and in combination with cemiplimab in patients with prostate cancer

UVA Tracking #
HSR210147
Principal Investigator
Robert Dreicer
Contact
Contact Phone
Official Trial Title
First-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W_pro1 (BNT112) monotherapy and in combination with cemiplimab in patients with prostate cancer
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have prostate cancer. W_pro1 is an immune treatment composed of “messenger Ribonucleic Acid” or mRNA, and will either be given alone (as monotherapy) or in combination with cemiplimab, a human monoclonal antibody, in patients with prostate cancer. The trial will investigate whether W_pro1 either alone or in combination with cemiplimab will be safe and beneficial for your type of prostate cancer.

You will be randomly assigned to receive either W-pro1 alone (Arm 1B), or in combination with cemiplimab. The total treatment duration is unknown as you will receive W_pro1 and, if applicable, cemiplimab as long as your disease status does not worsen or no other reasons for stopping occur

Study-related procedures that are being done beyond your standard of care will be provided at no cost to
your or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04382898

uvacancertrials@hscmail.mcc.virginia.edu

Compensation

$50 stipend per visit Up to $175 for hotel, per night